Integrated Pharmaceuticals, Inc.
(Public, OTC:INTP) Watch this stockFind more results for
INTP
Advertisement
Key stats and ratios
| Q2 (Jun '08) | 2007 | |
| Net profit margin | - | -5240.00% |
| Operating margin | - | -5217.14% |
| EBITD margin | - | -3665.71% |
| Return on average assets | -183.48% | -103.73% |
| Return on average equity | -270.07% | -128.25% |
| Employees | 4 | - |
Address
310 Authority Drive
Fitchburg,
United Arab Emirates
+971-978-6960020 (Phone)
+971-978-6960026 (Fax)
Fitchburg,
United Arab Emirates
+971-978-6960020 (Phone)
+971-978-6960026 (Fax)
Integrated Pharmaceuticals, Inc. discussions
View all discussions »Description
Integrated Pharmaceuticals, Inc. is a development-stage company. As of June 30, 2008, the Company is engaged in the development of clinically active pharmaceutical compounds, including active small molecules and recombinant deoxyribonucleic acid (DNA) technology derived products.
Officers and directors
| Peter Smith Featherston | President, Director | |
| David H. Smith II | Chief Financial Officer, Director | |
| Nilu Prasad Chatterjee Ph.D. | Vice President - Research & Development, Director | |
| Sally Johnson-Chin | Director | |
| Kenneth P. Wlosek | Director |